An innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies for rare and non-rare diseases.
- Year invested 2019
- Investment Stage Seed
- Board Members
- Sectors
- Investment Status Current
- Website affiniatx.com
- Company Status Private